Stay updated with breaking news from Registry Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patientsAD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRFirst approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expe...
Press release content from Business Wire. The AP news staff was not involved in its creation.
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use recommends approval of Kapruvia® as first therapy in Europe for the treatment of chronic kidney... | February 28, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia(difelikefalin) as first therapy in Europe for the treatment of
Interest in stenting for the treatment of symptomatic high-grade intracranial atherosclerosis may be rekindled after the results of a new trial using a drug-eluting stent.